audio interview today on boardroom radio , page-10

Here is a reply from Dermott when questioned about the reason he gave on the radio interview for the downturn in EMS SP.

Hi,

In answer to the question asked, we understand this has caused concern for some in the market. As to what Phase IIa is and what Phase III is often really comes down to the size of the trial. It had been our intention for the Rwanda trial to be categorised as a Phase III, however advice to ProtoPharma who run the clinical trial on behalf of Eastland, from the governing bodies overseeing the trial suggested that due to the fact that we were conducting a trial on very sick and very young children it was safest to initially adopt a conservative approach and restrict the size of the trial.



The important thing to stress is that we now have clear clinical evidence that the ArTiMist treatment works, as it delivered similar patient outcomes to IV infusion. We were committed to completing the trial process to gain additional clinical data as we are committed to building a strong clinical dossier of evidence that will enhance the attractiveness and value of the project to potential commercial partners.



Regards,



Dermot Patterson -

CEO and Company Secretary